Growth hormone treatment and bone mineral density in pediatric patients with Prader–Willi syndrome
Author:
Oto Yuji1, Murakami Nobuyuki1, Inoue Takeshi1, Matsubara Keiko2, Saima Sohei3, Ogata Hiroyuki3, Ihara Hiroshi3, Nagai Toshiro4, Matsubara Tomoyo1
Affiliation:
1. Department of Pediatrics , Dokkyo Medical University Saitama Medical Center , Saitama , Japan 2. Department of Molecular Endocrinology , National Research Institute for Child Health and Development , Tokyo , Japan 3. Department of Psychiatry , Dokkyo Medical University Saitama Medical Center , Saitama , Japan 4. Nakagawanosato Ryoiku Center , Saitama , Japan
Abstract
Abstract
Objectives
Previous reports indicate that growth hormone (GH) treatment for Prader–Willi syndrome (PWS) improves bone mineral density (BMD) only when initiated at a young age and not when initiated in adulthood. However, there are no data on BMD during long-term GH treatment of Japanese children and adolescents with PWS. Thus, this study aimed to investigate BMD changes among patients with PWS, who were undergoing GH treatment from childhood to adolescence.
Methods
Sixty-seven pediatric patients with PWS who had GH treatment initiated during childhood between January 2003 and June 2020 were evaluated. To avoid underestimation, we used total body BMD, which was evaluated using dual-X-ray absorptiometry adjusted for the BMD z-score using patient height, sex, and age.
Results
In both sexes, age was negatively correlated with the BMD-standard deviation score (SDS) (male: r=−0.156 [p=0.042]; female: r=−0.197 [p=0.043]), which started to decrease in childhood.
Conclusions
The BMD-SDS of patients with PWS decreases gradually despite GH treatment. As there are no clear recommendations about monitoring of bone health in patients with PWS, further studies are needed to improve the guidelines for screening of BMD and treatment of patients with PWS.
Publisher
Walter de Gruyter GmbH
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Pediatrics, Perinatology, and Child Health
Reference15 articles.
1. Butler, MG, Miller, JL, Forster, JL. Prader-Willi syndrome - clinical genetics, diagnosis and treatment approaches: an update. Curr Pediatr Rev 2019;15:207–44. https://doi.org/10.2174/1573396315666190716120925. 2. Donze, SH, Damen, L, Mahabier, EF, Hokken-Koelega, AC. Improved mental and motor development during 3 years of GH treatment in very young children with Prader-Willi syndrome. J Clin Endocrinol Metab 2018;103:3714–9. https://doi.org/10.1210/jc.2018-00687. 3. Butler, MG, Haber, L, Mernaugh, R, Carlson, MG, Price, R, Feurer, ID. Decreased bone mineral density in Prader-Willi syndrome: comparison with obese subjects. Am J Med Genet 2001;103:216–22. https://doi.org/10.1002/ajmg.1556. 4. Edouard, T, Deal, C, Van Vliet, G, Gaulin, N, Moreau, A, Rauch, F, et al.. Muscle-bone characteristics in children with Prader-Willi syndrome. J Clin Endocrinol Metab 2012;97:E275–81. https://doi.org/10.1210/jc.2011-2406. 5. Bakker, NE, Kuppens, RJ, Siemensma, EP, Tummers-de Lind van Wijngaarden, RF, Festen, DA, Bindels-de Heus, GC, et al.. Bone mineral density in children and adolescents with Prader-Willi syndrome: a longitudinal study during puberty and 9 years of growth hormone treatment. J Clin Endocrinol Metab 2015;100:1609–18. https://doi.org/10.1210/jc.2014-4347.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|